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Abstract Metabolic diseases—atherosclerotic cardiovas-
cular disease, type 2 diabetes mellitus, obesity, and non-
alcoholic fatty liver disease––have reached pandemic
proportions. Across gene, cell, organ, organism, and social-
environmental scales, fundamental discoveries of the
derangements that occur in these diseases are required to
develop effective new treatments. Here we will review
genetic, physiological, pathological and chemical biologi-
cal discoveries in the emerging zebrafish model for
studying metabolism and metabolic diseases. We present a
synthesis of recent studies using forward and reverse
genetic tools to make new contributions to our under-
standing of lipid trafficking, diabetes pathogenesis and
complications, and to b-cell biology. The technical and
physiological advantages and the pharmacological poten-
tial of this organism for discovery and validation of
metabolic disease targets are stressed by our summary of
recent findings. We conclude by arguing that metabolic
research using zebrafish will benefit from adoption of
conventional blood and tissue metabolite measurements,
employment of modern imaging techniques, and develop-
ment of more rigorous metabolic flux methods.
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Introduction
Global metabolic disease burden
The World Health Organization recently reaffirms that
cardiovascular disease remains the leading killer of adults
[1]; it is expected that global mortality from non-commu-
nicable diseases will increase in the coming decades, with
cardiovascular disease leading the way [2]. This prediction
is informed by the unabated increase in the prevalence of
cardiovascular risk factors such as tobacco exposure [2],
hypertension [3], obesity in children and adults [4], type 2
diabetes mellitus [5], and non-alcoholic fatty liver disease
(NAFLD) [6]. For type 2 diabetes mellitus, we are in the
midst of an accelerating pandemic, which has not only
increased the global death rate from this disease [1], but
has also caused a massive rise in the number of persons
living with disabling complications [7, 8]. We will dem-
onstrate in this review that zebrafish is an excellent system
to discover and characterize new diagnostic and therapeutic
targets for metabolic diseases. We will attempt to focus on
those properties that make metabolic research in zebrafish
potentially transformative, citing original work as much as
possible throughout the remainder of this article.
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Zebrafish model overview
The general strengths of zebrafish for biomedical research
are well known: rapid external development, optical trans-
parency of the fertilized embryo, tractable genetics, and
ease of maintenance are marks of this model organism. The
animal’s conventional vertebrate body plan, which includes
central and autonomic nervous systems, digestive organs,
and adipose tissue is adopted early in development and is
amenable to rapid investigation. The digestive organs, for
instance, are fully functional by the larval stage (within a
few days of fertilization), and interrogation of their function
is feasible with genetic, physiological and chemical bio-
logical approaches largely because these organs remain
visible into the juvenile stage of development (Fig. 1).
Increasingly, adult zebrafish are being used for mechanistic
work, and we will highlight cases where metabolic research
advances have been made in this context.
Beyond these husbandry and life-cycle considerations,
zebrafish afford the investigator an attractive palette of sci-
entific approaches. Among vertebrate models, zebrafish is
unique in that unbiased, ‘‘forward’’ genetic screens to dis-
cover new factors involved in a limitless number of processes
[9], high-throughput platforms for discovery of small
molecular handles of physiology [10], and emerging gene
editing capability for ‘‘reverse’’ genetic studies [11–13] are
all feasible on a large scale. For studying metabolism, as will
be described below, all three paradigms have been employed
fruitfully. Mutants identified in forward genetic screens have
illuminated aspects of metabolism; small molecules identi-
fied from screening of chemical libraries for compounds that
modulate metabolic programs have been reported; and
hypothesis-driven targeted ablation of select genes of met-
abolic interest has yielded novel results.
Lipoprotein metabolism and atherosclerosis models
Lipoprotein particles, carriers of structural lipids
and lipid-modified morphogens
Metazoans have a highly conserved system for transporting
water-insoluble lipids [14]. In particular, the b-lipoprotein
super-family, which includes Apolipoprotein B (verte-
brates only), and Apolipophorins (insects only), serves as
the signature scaffold for lipoprotein particles synthesized
by and secreted from the yolk, the intestine, and liver to
deliver sterols, sterol esters, and fatty acyl esters of glyc-
erol from their sites of absorption or synthesis to their sites
of use (Fig. 2a, b). An exciting concept that has emerged
through a genetic screen in zebrafish is the notion that
lipoprotein particles may carry signals directing angio-
genesis. First, a mutant whose capacity to produce Apob-
containing particles demonstrated diminished revealed
defective vessel growth [15]. The mutated gene micro-
somal triglyceride transfer protein (mtp) is expressed in the
yolk syncytial layer, liver and intestine, where it catalyzes
the lipidation of newly formed Apob [16, 17]. Second,
modulating the function of high-density lipoprotein (HDL)
particle biogenesis in zebrafish embryos [18] through
depletion of the Apolipoprotein A1 binding protein (Aibp)
increases endothelial plasma membrane cholesterol con-
tent, a process that interferes with the normal signaling
of Vascular endothelial growth factor receptor 2 (Vegfr2)
[18]; the ultimate effect of Aibp depletion is defective
vessel sprouting and branching. We posit that in addition to
the cell-autonomous alterations in Vegf signaling caused
by loss of mtp and aibp, cell-nonautonomous defects in
delivery of signaling molecules might contribute the
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shown that lipid modified morphogens such as Wingless
and Hedgehog are loaded onto lipoproteins for long-dis-
tance transport [19, 20]. In the case of Sonic Hedgehog
secreted by HeLa cells, Apob- and Apoa-containing lipo-
protein particles can incorporate these lipidated
morphogens [19, 21]. Thus, in addition to carrying neutral
lipids for structural and energy needs, lipoprotein particles
serve as carriers of lipid-modified signaling molecules that
exert hormone-like actions far from their sites of produc-
tion. It is tempting to speculate that the mtp mutant fails to
deliver a lipid-modified morphogen to blood vessels in b-
lipoprotein particles, thereby causing the perturbation of
the expression of the decoy vascular endothelial growth
factor receptor Vegfr1 [15].
Dyslipidemia models
Following release into the circulation, lipoproteins are
modified in zebrafish blood by machinery that is also
highly conserved in evolution. For instance, zebrafish carry
an ortholog of the human Cholesteryl Ester Transfer Pro-
tein (CETP) gene [22], whose encoded protein transfers
cholesteryl esters from HDL particles to low-density lipo-
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Fig. 2 Lipid trafficking in enterocytes and hepatocytes relies on the
same evolutionarily central machinery. a In the intestine dietary fats
are suspended in micelles in the lumen. Cholesterol (C) and plant
sterols (PS) are absorbed at the apical surface of enterocytes by
NPCL1L1. Plant sterols are immediately excreted back into the lumen
by the action of ABCG5/ABCG8 heterodimers. Following hydrolysis
of triacylglycerol (TAG), fatty acids (FAs) are transported across the
apical surface. Absorbed C and FAs are reassembled in the
endoplasmic reticulum (ER) into cholesteryl esters (CE) and TAG
by a series of enzymes (none are shown). ER-assembled neutral lipids
are packaged with Apolipoprotein B (ApoB) into nascent chylomi-
crons by Microsomal triglyceride transfer protein (MTP), which then
mature as they pass through the Golgi apparatus and are secreted into
the basolateral space. In parallel, Apolipoprotein A1 (Apoa1) is
release along the basolateral surface, where it combines with ABCA1-
transported free C to form nascent HDL particles. b In the liver, MTP
packages CE and TAG to make very low-density lipoprotein (VLDL)
particles, which are secreted across the basolateral surface into
lymphatic vessels. VLDL particles mature in the vasculature into
LDL particles that are retrieved by the LDL Receptor (LDLR), which
then undergoes endocytosis. Cholesterol is ultimately liberated
following degradation of these particles. Free fatty acids are also
transported across this surface from the circulation by transporters
that are not shown. NPC1L1 and the ABCG5/ABCG8 complex reside
on the apical, bile canalicular surface where they serve to retrieve or
eliminate (respectively) cholesterol from the bile. Both cell types
have the capacity to form cytoplasmic lipid droplets. The molecular
cues governing this storage are largely not known. Chylomicrons
enter the lymphatic circulation, by-passing perfusion of the liver
through the portal circulation. VLDL particles enter the circulation
via the hepatic vein
Metabolic insights from zebrafish genetics 2251
123
cholesterol levels and increasing atherogenic LDL-choles-
terol levels [23]. A Cetp ortholog is absent in commonly
used rodent models, rendering the study of atherosclerosis
difficult: rodents are inherently resistant to atherosclerosis
because, among other things, they lack this enzyme’s
action [24]. There is no a priori guarantee that zebrafish
atheromas will model the full natural history of the human
disease more closely; however, retention of the cetp gene
in teleost fish such as zebrafish causes the circulating
lipoproteins to resemble human lipoproteins in abundance
and composition [25]. This conserved lipoprotein metab-
olism (high concentration of LDL particles and low
concentration of HDL particles) contributes to the rapid
susceptibility of zebrafish to atherosclerosis when placed
on a high cholesterol diet [26, 27]. Additionally, the
deposition of sub-intimal cholesterol can be monitored in
real time, in live zebrafish larvae, affording an ‘‘in vivo cell
biological’’ view of atherogenesis [28, 29]. We anticipate
that studying the natural history of atheroma progression––
from simple lipid accumulation below the vasculature to
organization into ‘‘complex,’’ plaques should be feasible in
zebrafish.
Zebrafish bearing a targeted deletion mutation of the
master transcription factor of cholesterol catabolism
Liver x receptor alpha (nr1h3) gene develop severe
hypercholesterolemia and hepatic steatosis when fed high-
cholesterol and high-fat diets [30]. Conversely, over-
expression of nr1h3 in enterocytes confers protection from
dyslipidemia and hepatic steatosis when animals are fed a
high fat diet. This metabolically beneficial effect of nr1h3
over-expression is due to induction of a transcriptional
program resulting in temporary enterocyte storage of lipids,
delaying an en masse delivery of atherogenic lipoprotein
particles in the circulation. This single gene deletion model
might be useful for studying atherogenesis since the
mutants are viable and fertile.
Hepatic steatosis models
The clinical problem
Accumulation of lipids (hepatic steatosis) is very com-
monly observed in obese persons. Hepatic steatosis is
associated with insulin resistance, risk of coronary artery
disease and early atherosclerosis [6, 31], although findings
from human genome-wide association studies have not
provided a clear hypothesis on causality or directionality
for these associations [32]. NAFLD encompasses hepatic
steatosis and several pathological states that follow it:
inflammation (steatohepatitis), fibrosis (cirrhosis) and
cancer (hepatocellular carcinoma). There are limited ther-
apeutic options for permanently ameliorating hepatic
steatosis and there are no methods for reversing hepatic
fibrosis, or preventing hepatocellular carcinoma due to
NAFLD [12].
The first step of NAFLD is the inappropriate accumu-
lation of triacylglycerol in the hepatocyte. This
accumulation may be due to excessive de novo hepatic
lipid production, decreased hepatic secretion of very low-
density lipoprotein particles, diminished b-oxidation of
fatty acids in the liver, more subtle defects in regulating
energy homeostasis including insulin resistance or central
nervous system nutrient sensing, or a combination of these
factors [33]. Since each of these steps could be amenable to
therapeutic exploitation, understanding their regulation is
paramount. As outlined below, zebrafish have proven to be
useful in elucidating previously unappreciated aspects of
hepatic lipid metabolism. These findings may serve as the
basis for rational development of new diagnostic and
therapeutic modalities.
Zebrafish genetic and dietary studies
Previously, we reviewed the major findings of the steatosis
phenotypes of five reported zebrafish mutants [34]. The
affected genes encode structural proteins (Trafficking
protein particle complex 11), signaling molecules (Serine/
threonine kinase 11, also called Lkb1), enzymes of inter-
mediary metabolism (S-adenosyl-homocysteine hydrolase),
and transporters of metabolites (Solute carrier family 16,
member 6a, Slc16a6a). All appear to act cell-autonomously
in the hepatocyte. While each case has advanced knowl-
edge of an interesting facet of biology, none recapitulates
the full spectrum of human NAFLD phenotypes. In cases
where mutants are viable beyond the early larval period,
studies of adults might allow investigators the ability to test
whether the underlying molecular lesion serves to sensitize
the liver to inflammation, fibrosis and cancer. It is critical,
however, that the global effects of diets on growth be
considered when defined diets are used to trigger hepatic
steatosis in these genetic models [35].
Another very promising approach to modeling NAFLD
in zebrafish involves triggering steatosis with dietary
interventions. Simply over-feeding zebrafish their normal
live dietary supplement (Artemia brine shrimp) causes
obesity within 8 weeks, hypertriglyceridemia, and hepatic
steatosis [36]. Also, this study revealed conserved adipo-
cyte gene expression changes in obesity. Although liver
gene expression differences were not reported, this study
demonstrated that significant metabolic changes can be
generated through relatively short dietary interventions.
Similarly, feeding zebrafish larvae fructose for 48 h is
sufficient to induce hepatic steatosis, and activation of
inflammatory and lipogenic gene expression [37]. Fur-
thermore, fructose-induced steatosis could be reversed
2252 A. Schlegel, P. Gut
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through inhibiting the evolutionarily central nutrient-sens-
ing kinase Mechanistic target of rapamycin (Mtor). We
anticipate that longer studies of high fructose diets will
yield important findings.
Using a fortuitously generated insertion mutant [38], Cui
and colleagues were able to examine the consequences of
inactivating the gene encoding the arginine transporter
Slc7a3a in hepatic lipid biology [39]. Specifically, the
authors found that by hindering hepatocyte uptake of this
cationic amino acid critical for nitric oxide production, the
slc7a3a mutation perturbed a signaling cascade that
includes activation of the AMK-dependent kinase and
activation of the master nuclear receptor of fatty acid
oxidation Peroxisome proliferator-activated receptor a
(Ppara) [39]. The fasting hepatic steatosis phenotype of the
slc7a3a mutant zebrafish larvae was recapitulated in mouse
livers and cultured human hepatocytes when the ortholo-
gous genes were knocked-down. The slc7a3a mutant
larvae are sensitive to starvation, a phenotype reminiscent
of the nutritionally suppressible hepatic steatosis we found
in slc16a6a mutants, which are incapable of exporting
ketone bodies (partially oxidized fatty acids that can be
used by the brain and heart during starvation) from the liver
[40]. Like the slc16a6a mutants, slc7a3a mutants are via-
ble and fertile, and when fasted as adults they develop
hepatic steatosis. Four separate Ppara agonists failed to
rescue the hepatic steatosis phenotype in slc16a6a mutants,
suggesting that defective ketone body export is a bottle-
neck of fasting metabolism. It will be interesting to learn
whether ketogenic diets, which cause development of
hepatic steatosis in adult slc16a6a mutants [35], also trig-
ger hepatic steatosis, hepatic inflammation, or both in
slc7a3a mutants. Finally, the slc7a3a mutant underscores
the centrality of AMP-dependent kinase energy sensing to
normal hepatocyte coordination of metabolism: mutation
of the Stk11 kinase (up-stream of AMP-kinase) causes a
fasting hepatic steatosis phenotype in zebrafish, as well
[41]. Interestingly, lkb1 mutants also fail to feed and have
altered intestinal architectural phenotypes, revealing
nuances beyond regulation of fasting liver lipid metabo-
lism among components of the AMP-kinase pathway.
Adipose biology
Ontogeny
A visceral adipose depot develops in adipocytes after lar-
vae commence feeding [42]. The stored lipids can be
visualized in vivo with fluorescent lipid dyes; such imaging
reveals that the adipose neutral lipid mass can be com-
pletely mobilized by starvation and restored by subsequent
return to adequate nutrition [42]. Discrete subcutaneous
adipose depots develop after this initial period. The num-
ber, size and location of adipocytes are functions of animal
body size [43], suggesting that adipose lipid accumulation
occurs once a critical body mass and length are reached.
Such body size-dependent development of adipose tissue is
consistent with other aspects of metamorphosis. The adult
skin pigmentation pattern, for example, is assumed during
the rapid growth of the late juvenile period, when multiple
cell types organize in the skin to generate the adult pattern
of stripes. This exquisite process is under the instruction on
the master vertebrate metamorphogen thyroid hormone
[44, 45]. The molecular cues controlling adipogenesis are
likely to be highly conserved in zebrafish: multiple markers
of adipocytes in higher vertebrates are expressed in zeb-
rafish adipose and the tissue undergoes conserved gene
expression changes when animals are rendered obese
through over-feeding [36].
Future directions for developmental biology, feeding,
energy expenditure, obesity
Fluorescent lipid dyes have been successfully used to
assess the effects of compounds on adipose lipid mass [46],
indicating that this cell type is amenable to live imaging
methods. Progress in studying adipocyte biology in zeb-
rafish has been limited by the lack of robust cellular
markers. To our knowledge no reporter lines that label
adipocytes specifically are present. Enthusiasm for con-
servation of expression of the mouse aP2 (Fabp4) ortholog
fabp11a in adipose tissue is muted by the realization that
this gene is widely expressed in mouse development [47].
Worse, several transgenic drivers using the aP2 promoter
do not label white adipocytes, but rather mark adipose
tissue endothelial cells in adult mice [48]. As described
below, one solution to this lack of markers might be
introduction of reporter constructs into endogenous loci
using new gene editing tools. Screening enhancer trap lines
for expression in adipose tissue might reveal adipocyte-
selective drivers, again with the caveat that establishing the
cell type labeled in this tissue will require careful immu-
nohistochemical staining [48]. Serendipitous insertion of a
transgenic driver prepared for study of a different cell type
has revealed a putative adipocyte-restricted enhancer locus,
indicating a systematic search for such drivers should be
feasible [49].
With an adipocyte driver in hand, researchers should be
able to perform more robust descriptive studies of zebrafish
adipocyte ontogeny, and may be poised to conduct facile
genetic or chemical screens for genes and small molecules
that modulate adipocyte number and lipid accumulation.
Likewise, examining the effects of feeding, fasting, and
exercise on adipocyte number and lipid mass could be done
in vivo with such tools. It is important to recognize that as
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poikilothermic organisms, zebrafish may not have the full
repertoire of developmental programs to make thermogenic
brown adipocytes, relying instead on modest, thyroid hor-
mone-driven transcriptional programs to generate heat in
their muscles [50]. Additionally, adult female adipocytes in
zebrafish participate in vitellogenesis, secreting lipoprotein
particles under the control of estrogens to deliver proteins
and lipids selectively to the ovary, where they are incor-
porated into oocyte yolk [51]. This elaborate selective
trafficking of lipids from adipose to ovary is not present in
mammals.
Glucose metabolism and diabetes mellitus models
The clinical problem
Pandemic diabetes mellitus has emerged in the span of a
few human generations. The vast majority of cases of this
condition are due to relative insulin deficiency caused by b-
cell failure in the setting of insulin resistance (type 2 dia-
betes mellitus). Autoimmune destruction of b-cells in type
1 diabetes mellitus is, fortunately, less common, but this
disease can present much earlier in life and is associated
with numerous, potentially debilitating and very expensive
sequelae, making it an important public health concern.
The cornerstones of mammalian glucose homeostasis
are conserved in zebrafish. Several general aspects of the
zebrafish glucose homeostatic machinery merit attention.
First, the endocrine pancreas of zebrafish is anatomically
embedded within the exocrine pancreas (Fig. 1) and
development of the mature structure occurs over two waves
or cellular movements similar to those that occur during
mammalian development [52, 53]. Second, zebrafish ini-
tiate gluconeogenesis during fasting [54–56], store and
catabolize glycogen [41, 57], and respond to insulin
injections by decreasing blood glucose [58]. Finally,
ablation of b-cells in adult and larval fish leads to hyper-
glycemia [59, 60]. Below, we summarize these and other
recent advances in our knowledge of zebrafish b-cell
development and regeneration, disease models of diabetes
and diabetic complications, and drug discovery (Fig. 3).
Chemical biological approaches for probing b-cell
plasticity
Regenerative strategies that restore b-cell mass and func-
tion are attractive goals for treating diabetes mellitus [61].
One challenge is to identify chemicals that are able to
affect b-cell plasticity in vivo. Towards this end, several
chemical genetics screens have been carried out in zebra-
fish that systematically tested the effects of small
molecules on b-cell proliferation [62], neogenesis [63] and
regeneration [60]. For many of the pathways that are tar-
geted by the hit compounds from these three screens,
evidence suggests that the underlying mechanisms may be
highly conserved. For instance, serotonin reuptake and
monoamine oxidase disrupting compounds enhance zeb-
rafish b-cell replication; serotonin is highly expressed in
mouseb-cells [64], and mediates the expansion of pancre-
atic b-cell mass in pregnant mice [65].
A screen for compounds that enhance b-cell regenera-
tion revealed that the majority of hit compounds from over
5,000 screened chemicals converge in the adenosine sig-
naling pathway or its downstream components [60]. The
strongest hit, NECA, had a dramatic stimulatory effect on
b-cell regeneration, and was able to also restore glucose
homeostasis and b-cell mass in mice that were subjected to
b-cell ablation. This finding was in support of a previous
study that showed regeneration of b-cells in diabetic mice
that were treated with NECA, although the recovery had
been attributed to anti-inflammatory effects induced by the
drug [66]. Additionally, adenosine kinase inhibitors, which
indirectly increase adenosine signaling, have been found in
a small molecule screen to enhance b-cell replication in
primary rodent and porcine b-cells [67]. Furthermore,
agonists of the A2A adenosine receptor have been shown in
humans to improve the outcome of islet transplantation
[68], pointing to adenosine signaling as a promising target
in b-cell regenerative medicine.
Another set of studies tested the effects of nutrition on b-
cell plasticity to address mechanisms that may contribute to
the increase in the b-cell pools that is commonly observed in
human obesity. First, lipids and glucose-enriched diets can
stimulate b-cell neogenesis through independent mecha-
nisms in zebrafish [69]. Lipids required insulin/IGF
signaling, whereas glucose-stimulated b-cell differentiation
depends on Mtor signaling. Lineage-tracing of progenitor
cells reveals that two types of precursors contributed to the
newly formed b-cells, nkx2.2 and mnx1 positive cells.
Second, Notch signaling in regulatingb-cell differentiation
is under nutritional control. Feeding starving larvae acutely
increases b-cell mass through endocrine differentiation of a
Notch-positive progenitor pool associated with the intrapan-
creatic duct (IPD) [70]. With the aid of lineage tracing tools,
Notch-positive progenitors were identified within the intra-
pancreatic ducts (IPDs) that can differentiate into b-cells [71].
Activation of the progenitor niche by nutrients required
activity of the energy sensor Mtor. Collectively, these studies
revealed that nutrients suppress Notch signaling selectively in
the IPD, allowing endocrine differentiation.
Overall a picture has emerged that the b-cell pool in
zebrafish retains a high degree of plasticity both in
response to nutrients and to small molecules, and the
underlying mechanisms can now be dissected in detail
using genetics, chemical biology and high-resolution live
2254 A. Schlegel, P. Gut
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imaging. From a nutritional perspective, it will be inter-
esting to identify which nutrients modulate Notch signaling
in endocrine progenitors, and and how these nutrients
prime these progenitor cells to contribute to the mature b-
cell mass.
Diabetic complications and glycemic memory
Evidence that diabetic complications can be modeled in
zebrafish has been reported recently. Following treatment
with streptozotocin, a b-cell selective cytotoxin, hyper-
glycemia persists for 3 weeks, leading to high levels of
glycated serum proteins (i.e., proteins damaged through
non-enzymatic reaction with glucose). Furthermore,
regeneration of the dorsal fin after amputation was
impaired in this hyperglycemic model [72]. Similarly,
intermittent hyperglycemic insults in 2-year-old zebrafish
using glucose-enriched water caused impaired vision and a
selective degeneration of cone photoreceptors [73]. In
addition, enlargement of the basal membrane of endothelial
cells was reported together with disrupted tight conjunc-
tions and an overall thickening of the vessels similar to
histological hallmarks of human retinopathy.
The risk for cardiovascular complications remains sig-
nificantly elevated in diabetics compared to healthy patients
even if continuous intensive glycemic control is achieved
[74, 75]. It has been hypothesized that a glycemic insult
during a restricted timeframe can leave a cellular ‘‘glycemic
memory’’ that contributes to later development of pathology
[76]. Dynamic changes in chromatin marks are known to
regulate gene expression and ultimately cellular behavior
over long-time spans, and are believed to be influenced by
signals from intermediary metabolism [77]. Studies in cel-
lular models and diabetic mice indicate that glycemic insults
can reprogram histone methylation marks in endothelial
cells. These chromatin modifications localize to promoters
of pro-inflammatory genes and correlate with chronically
increased gene expression and inflammation [78, 79].
Zebrafish fin regeneration is an experimental model that
has been used to directly test the hypothesis that acute
hyperglycemic insult can cause a harmful glycemic mem-
ory. In normoglycemic animals, full fin regeneration
usually occurs in larval and adult zebrafish in a matter of
days [80]. In fin-amputated zebrafish rendered hypergly-
cemic following b-cell ablation, regeneration of amputated
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Fig. 3 Factors identified by small molecule screens and dietary
interventions in zebrafish that modulate b-cell plasticity. The origin of
new b-cells can be roughly classified in differentiation from
progenitor cells (pathways marked by red boxes) and in proliferation
from existing b-cells (pathways marked by blue boxes). (1) Activators
of adenosine signaling enhance proliferation predominantly after
tissue damage. (2) The suppression of Notch signaling emerges as a
key requirement for differentiation from Notch-responsive cells
(NRC) within the intrapancreatic ducts (IPD) towards the endocrine
lineage. Pharmacological inhibition of Notch by the c-secretase
inhibitor DAPT is a strong enhancer of secondary islet formation
during zebrafish development. Down-regulation of Notch in NRCs
precedes new beta cell formation in response to high calorie diet in
normal physiology and after beta cell ablation. (3) Lipids and glucose
stimulate beta cell differentiation from post-mitotic progenitor cells
that are marked by mnx1 or nkx2.2. (4) DSF and MPA induce
precocious differentiation of endocrine cells from the IPD without
affecting Notch levels. Both compounds induce pax6:GFP positive
cells that can give rise to a- and b-cells. The small molecules listed
depict the most potent compounds and do not reflect all chemicals
found in the different chemical screens. GR glucocorticoid receptor,
RA retinoic acid, DSF disulfiram, MPA mycophenolic acid
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persisted after the b-cell pool and euglycemia had been
fully restored. Global DNA hypomethylation and differ-
ences in gene expression relating to wound healing were
also observed [81]. A follow-up study by the same group
showed that a transient hyperglycemic insult-induced
members of the Ten-Eleven Translocation (Tet) protein
family [82], which are known to catalyze the reaction of
5-methylcytosine of DNA to 5-hydroxmethylcystosine and
thereby mediate DNA demethylation [83]. Furthermore,
pharmacological inhibition of Poly(ADP-Ribose) Poly-
merase (PARP) enzymes, which are required for Tet
activity, with 1,5-isoquinolinediol reversed the DNA hy-
pomethylation phenotype and restored fin generation. We
expect these mechanistic insights may reveal therapeutic
targets for improving wound healing in the context of
diabetes mellitus. In summary, several studies suggest that
diabetic complications can be modeled in zebrafish.
Drug discovery and pharmacology
Phenotypic screens in cells have high-throughput capacities,
and are amenable to high-content approaches. In contrast,
screens in zebrafish are low to moderate throughput, but
have the unique advantage to be able to identify chemicals
that bypass xenobiotic defense mechanisms and homeostatic
feedback loops that control metabolism. While we will focus
on screens related to metabolic regulation, we note in
passing that simple, high fidelity assays for monitoring lipids
[84] can be used in a whole-mount method to screen com-
pounds that alter absorption, transport, or both of dietary
macronutrients [85].
A recent screen from our group has shown that the
fasting-inducible activation of gluconeogenesis can be
leveraged to identify molecules that affect energy metab-
olism and glucose homeostasis [56]. We identified ligands
of the translocator protein 18kd (TSPO) activate the Ppara-
driven fasting response in zebrafish and mice. These
compounds protected mice from glucose intolerance and
fatty liver when fed a high-fat diet. In addition, this screen
has identified several drug classes that are known to induce
iatrogenic diabetes as prominent adverse effect, including
glucocorticoids, atypical antipsychotics and tricyclic anti-
depressants. Thus, chemical screens in zebrafish can both
identify new modulators of glucose control as well as
pharmaceuticals with potential adverse metabolic effects.
Last, an in vivo strategy to identify direct or indirect
activators of glucocorticoid signaling using a biolumines-
cence glucocorticoid responsive reporter zebrafish line has
been developed [86]. It will be interesting to screen sys-
tematically clinically used drugs and environmental toxins
and to test the identified hit compounds that modulate glu-
cocorticoid reporter expression, and to test whether these
compounds alter glucose metabolism in whole animals.
Future directions
We see three areas where zebrafish metabolic research
can benefit from adoption of new technologies and
approaches. For example, metabolic research maybe
transformed through the wide-scale adoption of modern
reverse genetic tools [11–13]. In addition to allowing
investigators the ability to delete target genes, gene
editing reagents such as CRISPR-Cas9 and TALENs have
advanced to the point that knock-in of mutations or
reporter genes is feasible [87–89]. Modeling Mendelian
diseases with introduction of human disease alleles should
be a tractable goal with such tools. Knock-in technologies
should also allow investigators to explore facets of
development or physiology that have previously been
intractable because of the lack of informative reporters
[13]. New imaging methods that allow analysis of thick
samples such as light sheet microscopy [90] and X-ray
microtomography [91] may allow investigators to image
atherosclerotic plaque and adipocyte development in real
time in this organism well into the late larval and early
juvenile periods. Live fluorescent markers for the various
cell types in plaques such as endothelial cells, macro-
phages, and vascular smooth muscles will facilitate these
investigations [92]. Likewise, such reporters may be
useful in chemical or genetic screens for modifiers of
atherogenesis.
Second, we anticipate more investigators will prepare
and use defined diets for metabolic research with this
organism [93, 94]. As highlighted above, atherogenic and
ketogenic diets have been used successfully. The central
issue shall be to recognize that we lack a complete view of
the nutritional requirements of this organism over its life
cycle [95], and each experimental dietary study should
include careful recording of growth using standard aqua-
culture metrics [96]. Similarly, to our knowledge, no
zebrafish system has been developed yet that can mimic
chronic b-cell dysfunction, or peripheral insulin resistance.
Such reagents could be used to examine long-term conse-
quences of poor glycemic control. Establishing such
models will allow investigators to leverage the advantages
of the system to study the natural history of diabetes
progression.
Third, we anticipate advances in micro-scale proteomic
[97] and metabolomic [98] technologies to allow investi-
gators to tackle more sophisticated questions. These
methods can be tailored to unique biological questions that
are best addressed in vivo [99]. For instance, we envision
stable isotope approaches to be optimized to allow inves-
tigators the ability to interrogate kinetics of glucose and
lipid metabolism. Such flux studies will provide mecha-
nistic understanding that snap shots of metabolite
abundance lack. Other whole-animal physiological
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measurements like mitochondrial respiration should be
standardized, as well [100].
Conclusions
Through a combination of genetic, developmental, and
physiological advantages, the zebrafish has emerged as a
major mechanistic discovery platform for studying
metabolism and modeling metabolic diseases. Here we
highlighted individual areas of success using this organism.
Further work is required to leverage the power of the
system to develop new and effective therapies.
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